28bio announced the launch of CNS-3D Myelinated Organoids, an assay-ready 3D human brain organoid model specifically designed to quantify myelin loss, observe natural remyelination, and evaluate dose-dependent myelin repair by therapeutics.
The organoids include neurons, astrocytes, and oligodendrocytes organized in a three-dimensional structure that supports the formation of myelinated axons, enabling simultaneous readouts of structural, molecular, and functional neural activity endpoints.
This platform aims to address limitations of traditional animal models, where myelin loss and repair occur faster and more completely than in humans, creating a translational gap for diseases such as multiple sclerosis and other demyelinating and neurodegenerative disorders.
CNS-3D Myelinated Organoids allow direct measurement of myelin dynamics (loss and recovery) and functional neural activity in a human-derived system, enabling more accurate prediction of therapeutic efficacy and safety for myelin-targeting drugs.
The product is currently available as a service offering, with assay-ready 96- and 384-well replicate formats planned for global shipment starting in Q3 2026, targeting pharma and biotech companies developing CNS therapies.
28bio positions this launch as a key step toward comprehensive, human-relevant assays for modeling disease pathogenesis and functional recovery in neurodegenerative diseases, with the goal of improving clinical translation and reducing reliance on animal testing.
The CNS-3D Myelinated Organoid model is part of 28bio’s broader Nexon platform, which integrates tissue engineering, neural interfacing, and AI to create brain organoids that exhibit memory, learning, and cognitive-like functions for neurology drug development.